Trinity Biotech (TRIB) Expected to Post Earnings on Thursday

Trinity Biotech (NASDAQ:TRIB) is anticipated to release its Q2 2026 resultson Thursday, September 3rd. Analysts expect Trinity Biotech to announce earnings of ($7.80) per share and revenue of $10.3110 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, September 11, 2026 at 4:00 PM ET.

Trinity Biotech (NASDAQ:TRIB) last posted its earnings results on Tuesday, June 16th. The company reported ($6.90) EPS for the quarter, topping analysts’ consensus estimates of ($9.30) by $2.40. The company had revenue of $10.85 million during the quarter, compared to the consensus estimate of $10.68 million.

Trinity Biotech Price Performance

NASDAQ TRIB opened at $9.87 on Tuesday. The business’s fifty day moving average price is $11.21 and its 200-day moving average price is $16.97. The stock has a market capitalization of $7.99 million and a price-to-earnings ratio of -0.22. Trinity Biotech has a 1-year low of $7.94 and a 1-year high of $52.50.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Trinity Biotech stock. Citadel Advisors LLC lifted its stake in Trinity Biotech PLC (NASDAQ:TRIB) by 196.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,384 shares of the company’s stock after purchasing an additional 26,084 shares during the period. Citadel Advisors LLC owned 1.10% of Trinity Biotech worth $41,000 at the end of the most recent reporting period. Institutional investors own 78.97% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Trinity Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Trinity Biotech Company Profile

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.